{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:14:39Z","timestamp":1770509679581,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"DOI":"10.2146\/ajhp130441","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T20:04:49Z","timestamp":1392667489000},"page":"403-406","source":"Crossref","is-referenced-by-count":14,"title":["Eosinophilic pneumonia induced by ceftaroline"],"prefix":"10.1093","volume":"71","author":[{"given":"Carrie L.","family":"Griffiths","sequence":"first","affiliation":[{"name":"Wingate University School of Pharmacy (WUSOP), Wingate, NC, and Critical Care Clinical Pharmacist, Department of Pharmacy, Carolinas Medical Center, Charlotte, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristofer C.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"WUSOP."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee D.","family":"Pitt","sequence":"additional","affiliation":[{"name":"WUSOP."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Lovell","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Charlotte"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041210514613400_b1-0710403","volume-title":"Teflaro (ceftaroline fosamil) package insert","year":"2010"},{"key":"2019041210514613400_b2-0710403","first-page":"5","article-title":"Ceftaroline fosamil (Teflaro)\u2014a new iv cephalosporin","volume":"53","year":"2011","journal-title":"Med Lett Drugs Ther"},{"key":"2019041210514613400_b3-0710403","unstructured":"Facts and Comparisons. Ceftaroline fosamil monograph. http:\/\/online.factsandcomparisons.com\/MonoDisp.aspx?monoID=fandc-hcp17871&quick=902990%7c5&search=902990%7c5&isstemmed=True&fromTop=true#firstMatch (accessed 2013 Jun 15)."},{"key":"2019041210514613400_b4-0710403","unstructured":"Lexicomp. Ceftaroline fosamil monograph. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/2940159 (accessed 2013 Jun 15)."},{"issue":"suppl 4","key":"2019041210514613400_b5-0710403","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporins with expanded anti-gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2019041210514613400_b6-0710403","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IPC.0b013e3182602205","article-title":"Use of ceftaroline in complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"21","author":"Zainah","year":"2013","journal-title":"Infect Dis Clin Pract"},{"key":"2019041210514613400_b7-0710403","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"2019041210514613400_b8-0710403","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2019041210514613400_b9-0710403","first-page":"149","article-title":"Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections","volume":"8","author":"Goodman","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"2019041210514613400_b10-0710403","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2019041210514613400_b11-0710403","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4046\/trd.2013.74.2.51","article-title":"Acute eosinophilic pneumonia","volume":"74","author":"Sohn","year":"2013","journal-title":"Tuberc Respir Dis"},{"key":"2019041210514613400_b12-0710403","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1398-9995.2005.00812.x","article-title":"Eosinophilic pneumonias","volume":"60","author":"Cottin","year":"2005","journal-title":"Allergy"},{"key":"2019041210514613400_b13-0710403","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00005792-196907000-00001","article-title":"The eosinophilic pneumonias","volume":"48","author":"Liebow","year":"1969","journal-title":"Medicine"},{"key":"2019041210514613400_b14-0710403","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2006-939522","article-title":"Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia","volume":"27","author":"Solomon","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"2019041210514613400_b15-0710403","first-page":"347","volume-title":"Basic skills in interpreting laboratory data","author":"Lee","year":"2009","edition":"4th ed"},{"key":"2019041210514613400_b16-0710403","unstructured":"Elsevier\/Gold Standard. Cefdinir monograph. http:\/\/clinicalpharmacology-ip.com\/Forms\/Monograph\/monograph.aspx?cpnum=688&sec=monadve&t=0 (accessed 2013 Jun 16)."},{"key":"2019041210514613400_b17-0710403","unstructured":"Elsevier\/Gold Standard. Daptomycin monograph. http:\/\/clinicalpharmacology-ip.com\/Forms\/Monograph\/monograph.aspx?cpnum=2280&sec=monadve&t=0 (accessed 2013 Jun 16)."},{"key":"2019041210514613400_b18-0710403","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bmj.294.6574.776-d","article-title":"Drug points: cephalexin associated pulmonary infiltration with circulating eosinophilia","volume":"294","author":"Smith","year":"1987","journal-title":"Br Med J"},{"key":"2019041210514613400_b19-0710403","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1378\/chest.86.1.138","article-title":"Cephalosporin-induced interstitial pneumonitis","volume":"86","author":"Dreis","year":"1984","journal-title":"Chest"},{"key":"2019041210514613400_b20-0710403","first-page":"1353","article-title":"Pulmonary infiltrates with eosinophilia possibly induced by cefotiam in a case of steroid-dependent asthma","volume":"28","author":"Irie","year":"1990","journal-title":"Jpn J Thorac Dis"},{"key":"2019041210514613400_b21-0710403","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/phar.1286","article-title":"Ceftaroline-induced eosinophilic pneumonia","volume":"33","author":"Desai","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"suppl 3","key":"2019041210514613400_b22-0710403","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2019041210514613400_b23-0710403","first-page":"iii53","article-title":"Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia","volume":"66","author":"Rank","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 4","key":"2019041210514613400_b24-0710403","first-page":"iv67","article-title":"Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corrado","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2019041210514613400_b25-0710403","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939517","article-title":"Acute eosinophilic pneumonia","volume":"27","author":"Allen","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"2019041210514613400_b26-0710403","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0272-5231(03)00141-2","article-title":"Drug-induced eosinophilic lung disease","volume":"25","author":"Allen","year":"2004","journal-title":"Clin Chest Med"},{"key":"2019041210514613400_b27-0710403","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1164\/ajrccm.160.4.9901075","article-title":"Corticosteroids in acute respiratory failure","volume":"160","author":"Jantz","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2019041210514613400_b28-0710403","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.147.10.3490","article-title":"Glucocorticoids inhibit cytokine-mediated eosinophil survival","volume":"147","author":"Wallen","year":"1991","journal-title":"J Immunol"},{"key":"2019041210514613400_b29-0710403","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/rg.273065051","article-title":"Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview","volume":"27","author":"Jeong","year":"2007","journal-title":"Radiographics"},{"key":"2019041210514613400_b30-0710403","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2019041210514613400_b31-0710403","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jemermed.2011.05.035","article-title":"The use of cephalosporins in penicillin-allergic patients: a literature review","volume":"42","author":"Campagna","year":"2012","journal-title":"J Emerg Med"},{"key":"2019041210514613400_b32-0710403","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"2019041210514613400_b33-0710403","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1398-9995.1979.tb02005.x","article-title":"The role of the eosinophil granulocyte in the inflammatory reaction","volume":"34","author":"Olsson","year":"1979","journal-title":"Allergy"},{"key":"2019041210514613400_b34-0710403","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ajh.22062","article-title":"World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management","volume":"86","author":"Gotlib","year":"2011","journal-title":"Am J Hematol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/5\/403\/28372311\/ajhp0403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T14:35:39Z","timestamp":1688999739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/5\/403\/5111258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130441","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,3,1]]},"published":{"date-parts":[[2014,3,1]]}}}